Medical cannabis, or cannabinoid-based products, continues to grow in popularity globally, driving the evolution of regulatory access frameworks; cancer patients and caregivers often rely on guidance from their physicians regarding cannabinoid-based treatments.
Insufficient management of cancer-associated chronic and neuropathic pain adversely affects patient quality of life.
Insufficient management of cancer-associated chronic and neuropathic pain adversely affects patient quality of life.
The use of medical marijuana in cancer care presents a dilemma for both patients and physicians.
Marijuana generally refers to the dried mixture of leaves and flowers of the cannabis plant, and the term cannabis is a commonly used to refer to products derived from the Cannabis sativa L. plant.
The purpose of this report is to present a review of the medical uses, efficacy, and adverse effects of the three approved cannabis-based medications and ingested marijuana.
Cannabis has the potential to modulate some of the most common and debilitating symptoms of cancer and its treatments, including nausea and vomiting, loss of appetite, and pain.
Policy discussions amidst recent changes in the legal status of cannabis for medical purposes have raised concerns regarding the diversion of medical cannabis to nonlicensed users.
Fibromyalgia is a chronic pain syndrome, characterized by chronic musculoskeletal pain, fatigue, and mood disturbances. There are nearly no data on the effect of medical cannabis (MC) treatment on patients with fibromyalgia.
Medical cannabis use is common in the United States and increasingly more socially acceptable.
